Marshall Wace’s Outlook Therapeutics OTLK Stock Holding History

Marshall Wace’s Portfolio OTLK Stock Details OTLK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.16M	Buy	+1,987,578	New	+$1.23M	﹤0.01%	1598
2026 Q1	–	Sell	-298,456	Closed	-$472K	–	3558
2025 Q4	$472K	Buy	+298,456	New	+$477K	﹤0.01%	2259
2025 Q3	–	Sell	-25,564	Closed	-$40.9K	–	3270
2025 Q2	$40.9K	Buy	+25,564	New	+$40.8K	﹤0.01%	2609
2022 Q2	–	Sell	-2,014	Closed	-$71K	–	3729
2022 Q1	$71K	Sell	2,014 -5,664	-74%	-$177K	﹤0.01%	3225
2021 Q4	$209K	Buy	+7,678	New	+$274K	﹤0.01%	3144
2021 Q2	–	Sell	-4,041	Closed	-$182K	–	2967
2021 Q1	$182K	Buy	+4,041	New	+$155K	﹤0.01%	2287
2017 Q1	–	Sell	-1,636	Closed	-$788K	–	626
2016 Q4	$788K	Buy	1,636 +72	+5%	+$40.3K	0.01%	786
2016 Q3	$1.06M	Hold	1,564	–	–	0.01%	708
2016 Q2	$851K	Buy	+1,564	New	+$933K	0.01%	744

Other funds holding OTLK

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

GWM

Gilpin Wealth Management Denver, Colorado $145M AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Marshall Wace's OTLK Position: Q2 2026 in Review

Marshall Wace opened a new position in Outlook Therapeutics (OTLK) in Q2 2026: 1,987,578 shares worth $3.16M. The stake represents ﹤0.01% of the portfolio and ranks #1598 among its holdings. This is a return to the name: Marshall Wace previously reported a position in OTLK as recently as Q4 2025.

Marshall Wace first reported a position in OTLK in Q2 2016 and has held it in 9 quarters since. 69 funds tracked by Wall St. Rank hold OTLK as of Q2 2026.

Marshall Wace held 1,987,578 shares of Outlook Therapeutics worth $3.16M as of Q2 2026.
Outlook Therapeutics was a new Marshall Wace position in Q2 2026.
Outlook Therapeutics made up ﹤0.01% of Marshall Wace's portfolio in Q2 2026, its #1598 holding.
Marshall Wace first reported a position in Outlook Therapeutics in Q2 2016 and has held it in 9 quarters since.
69 funds tracked by Wall St. Rank held Outlook Therapeutics as of Q2 2026.

Based on Marshall Wace's 13F filing for Q2 2026, filed 13 Aug 2026.